REVIEW article
Front. Med.
Sec. Nephrology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1560222
Application of biomarkers in the diagnosis of kidney disease
Provisionally accepted
- 1Gongli Hospital of Shanghai Pudong New Area, Shanghai, China
- 2Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong Province, China
- 3Goldsite Diagnostics Inc., Shenzhen, China
- 4Baotou Central Hospital, Baotou, China
- 5Guilin Hospital of Integrated Traditional Chinese and Western Medicine, Guilin, China
- 6Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China
- 7First Affiliated Hospital, Dalian Medical University, Dalian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Worldwide, kidney disease has grown to be an important global public health agenda that reduces longevity. Medical institutions around the globe should enhance screening efforts for kidney disease, to facilitate early kidney disease detection, diagnosis, and intervention. Common screening methods for nephropathy encompass renal tissue biopsy, urine dry chemistry tests, urine formed element analysis, and urine-specific protein assays, among others. These methodologies evaluate renal health by scrutinizing a spectrum of biomarkers. Precise classification and quantitative analysis of these biomarkers can assist in determining the site and extent of kidney injury, as well as in assessing treatment efficacy and prognosis. In this paper, we reviewed the methods and biomarkers for kidney disease and also the integration of multiple biomarkers. With the aim of reasonable applying these markers to the early detection, accurate diagnosis, and scientific management of kidney disease, thereby mitigating the threat posed by kidney disease to human health.
Keywords: biomarker, kidney disease, Chronic Kidney Disease, CKD, Acute kidney disease, AKD, kidney injury, Biomarker combination
Received: 14 Jan 2025; Accepted: 16 Apr 2025.
Copyright: © 2025 Lu, Ni, Wu, Zhai, Zhao, Zheng, Liu and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qianqian Liu, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China
Dapeng Ding, First Affiliated Hospital, Dalian Medical University, Dalian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.